transcript   Transcript

Securities Fraud Litigation Against Life Sciences Companies – Recent Trends

Recorded on: Jun. 22, 2018
Running Time: 01:02:55

Full Transcript:



If you are a Privileged Member, just log in and start reading now! If you are not a Privileged Member, please click here to learn how unlimited access to PLI programs may be right for you and your firm.

To access the streaming media of this presentation, please purchase the corresponding seminar segment.

Taken from the Audio-only Briefing Securities Fraud Litigation Against Life Sciences Companies – Recent Trends Recorded June 2018 in New York

Securities Fraud Litigation Against Life Sciences Companies – Recent Trends [01:02:55]

The life sciences industry continues to be a key target for securities fraud litigation and there is no indication that this trend will reverse any time soon.  As a result, life sciences companies must have a firm grasp on the recent developments in this area of the law, including the nature of the claims being brought, how courts throughout the country are reacting to various types of claims, and best practices firms can employ to avoid securities fraud litigation.  This analysis is particularly helpful with an overall backdrop of the current state of securities fraud litigation both domestically and globally.

Please join David H. Kistenbroker, Esq. and Joni S. Jacobsen, Esq. of Dechert LLP as they address: 
  • The dramatic increase in securities fraud cases in 2017, including against life science companies, and how to assess the risk of being subject to such litigation
  • The globalization of securities fraud litigation and how that relates to and impacts domestic claims
  • Trends in the types of securities fraud cases being filed and how they relate to the life cycle of the approval process
  • Courts’ reaction to the increased filings and analysis regarding which types of claims are more likely to survive a motion to dismiss
  • Best practices firms can employ to minimize the risk of securities fraud litigation

Program Level: Update

Intended Audience: In-house counsel, board members, outside attorneys, corporate officers, and other allied professionals responsible for the preparation of public reporting and disclosure documents relating to companies in the life sciences industry

Prerequisites: A familiarization with the preparation of public reporting and disclosure documents, particularly with respect to companies in the life sciences industry

Advanced Preparation: None

Presentation Material

  • Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies
    Joni S. Jacobsen, David H. Kistenbroker
  • Share
    Email
    Transcript FAQ's
    • How Can I Access Transcripts?
      You must be a Member in good standing.

    • Can I access the Video?
      Yes, you can access the video if you have the Adobe Flash plugin installed. Click on the video camera icon when you mouse over each paragraph. The media will begin playback at that point.

    • Can I get CLE credit for reading the transcript?
      No, CLE credit cannot be earned for reading a transcript. CLE credit is issued only for verified attendance while watching a web program. If seeking credit, please verify the program's eligibility for credit and expiration date in your jurisdiction on the web segment launch page before commencing the program.
    
    • FOLLOW PLI:
    • twitter
    • LinkedIn
    • YouTube
    • RSS

    All Contents Copyright © 1996-2018 Practising Law Institute. Continuing Legal Education since 1933.

    © 2018 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.